

Human Research Ethics Committee Initial Application for

Ethics Approval for Research Involving Humans

OFFICE USE ONLY:

Register No:

Date Received:

	E: This form is to be used for applications to U se this form to renew an existing approval or to approved project – refer to <i>Application for Amendment</i>	ply fo	or approval of additions or	
To tie	ck the hospitals at which you wish to conduct this pok.:	resea	rch, double-click on the app	propriate box, click on Checked,
	☐ The Wesley Hosp	ital,	Brisbane	
			norial Hospital, Brisbane	
	Sunshine Coast P			
	St Stephen's Hosp	oital,	Maryborough	
1	SHORT TITLE OF PROJECT			
2	APPROVAL FROM ANOTHER ETHICS Has this project been submitted (or will be s Ethics Committee for approval?	ubmi	itted) to another	Yes
	If YES: Name the committee(s), and give the	statı	is of each application.	(Attach copies of correspondence)
	Name of Ethics Committee and Institution		Application Reference No	Approved / Pending/ Rejected / To be submitted
				,
3	Name: Title / first name / family name	SUP.	ERVISOR (Note: only o	one person to be named)
	That is the first name / family name			
	Qualifications and position held:			
	Organisational unit and mailing address:			
	Talambana and Fave			
	Telephone and Fax: Email address:			
	Is the Chief Investigator an accredited	(ho	spital name)	
	practitioner at a Uniting Church hospital?			
4	CO-INVESTIGATORS and/or STUDEN	ΓRI	ESEARCHER	
	Name: Title / first name / family name			
	Qualifications and position(s) held:			
	Organisational unit and mailing address:			
	Telephone and Fax:			
	Email address:			
	Is this Co-Investigator an accredited	(ho	spital name)	

practitioner at a Uniting Church hospital?

Name: <i>Title / first nam</i> Qualifications and position	ne / family name on(s) held:							
Organisational unit and r	nailing address:							
Telephone and Fax: Email address: Is this Co-Investigator an practitioner at a Uniting Copy table and repeat for each	Church hospital?	(hospital name)						
STUDENT RESEARCH Is the research the project educational institution in If YES:	of a student of a u	niversity or other	tertiary		Yes		No	
Name of student: Course of study: Principal supervisor:				Studen	t No:			
ESTIMATED DURATION This is the period during we tissue samples. From:		te contact with pa	articipa	nts, thei	r person	al recor	ds, or h	uman
FUNDING Is the project the subject of external grants body, drug If YES (a) List the funding sour Funding Body	g company, etc?	-	olication		Yes	Cod/To be s	No	
			777					
(b) What is the exa	act project title or	n the funding a	oplicat	ion(s)?				
(c) Is there any affiliation or supervisor associated and the supe			sponso	or/fundin	ıg body :	and the	researc	her(s)
(d) Are there any condit If <i>Yes</i> : Please provide d	_	s research by the	fundin	g body?	Yes		No	
PRIVACY LEGISLATION Does the project involve a Commonwealth department	access to personal i			on?	Yes		No	
Does the project involve a	nccess to personal i ent or agency, or a personal information	private sector orgon be without the	anisatio				No No	
Does the project involve a Commonwealth departme	personal information information information related	private sector org on be without the es?	anisatio	nt of the	Yes	□ □ S/agencie	No	ng the

9 AIMS AND VALUE OF PROJECT Using plain English, provide a concise and simple description of your proposed research that sets out the background, precise aims/hypotheses/research questions, why you consider the research is worth doing, and what its potential merit and significance might be. Include references from your literature review to support the description. 10 REPLICATION STUDIES Has the same or a similar study been conducted in Australia or overseas? Yes If YES: Provide a brief statement giving your reasons and justification for wishing to replicate the work, with a brief but representative, literature review. 11 SPECIFIC TYPES OF RESEARCH Does the proposed research involve any of the following? Yes No Refer to the relevant section of the National Statement on Ethical Conduct in Research Involving Humans (designated NS...) and provide a statement detailing how your research protocol conforms to the requirements of the Statement. Yes No Children or young people under 18 years of age? (NS 4) No People with intellectual or mental impairment, temporary or permanent? (NSS) Yes People highly dependent on medical care, eg emergency care, intensive care, neonatal intensive care, terminally ill, or unconscious? (NS6) No Yes Aboriginal and Torres Strait Islander individuals, communities, or groups? П No (Guidelines and NS9) ATSIC cultural sensitivities should be respected. Yes If Yes, confirm that the requirements of National Statement Chapter 4.7 would be observed. Yes Other specific cultural, ethnic or indigenous groups? (NS8 - 'Collectivities') Yes No Assisted reproductive technology? (NS 11) Yes No Yes No Epidemiology research? (NS 14) No Use of human tissue samples? (NS 15) Yes Human genetic research? (NS 16) Yes No Deception of participants, concealment or covert observation? (NS 17) Yes No **12 CLINICAL TRIALS** Does the project involve the use of drugs, alternative or complementary therapies, therapeutic devices, or departure from standard treatment/care? Yes No If YES, complete and attach APPENDIX A. 13 **SAFETY IMPLICATIONS** Does the proposed research involve work on, use of, or exposure to any of the following? Genetically modified organisms No Yes Biologically hazardous materials Yes No Chemically hazardous materials Yes No Carcinogens Yes No **Teratogens** Yes No Radioisotopes Yes No

Ionising radiation

No

Yes

Non-ionising radiation Any other potential safety hazard for either participants or researchers?	Yes Yes		No No	
RESEARCH PLAN AND PROCEDURES Provide a plain English description of the proposed research plan and proheadings (for more information, refer to Guidelines):	ocedures,	using th	ne follow	ving
What is the research design/method?				
Where will the project be conducted? (Identify any hospitals, organisations, etc, that are to be involved.)				
Will the study involve staff or other resources on the part of Unitin facilities/services?	g <i>Care</i> He	alth		
What is the participant group(s) and why has it been selected?				
How many participants will be recruited and what is the rationale f	or that n	umber?	•	
How, by whom, and where, will potential participants be selected at the invitation to participate? (Attach copies of letters, advertisements, posters or other contents).				
How much time will potential participants have to consider the invi	itation to	particip	pate?	
What is required of participants? (Attach a copy of any surveys, interview schedules, data sheets, etc to be used.)				
Where will research activities involving participants be conducted?	ı			
Relevant experience of researchers.				
ANALYSIS Explain how the information you receive will be analysed/interpreted ana approaches or techniques (statistical or qualitative) will be employed?	d reported	. What s	specific	
PROPOSED REVIEW OF PROGRESS, PARTICIPANT CARE, ST PROCEDURES	TUDY CO)NCLU	SION	
Describe the mechanisms that will be put in place to deal with the follow	ing:			
Review of progress of the project.				
Duty of care to participants and research staff.				
Procedures for reporting adverse events.				
Premature cessation of project.				

17 SUMMARY OF ETHICAL CONSIDERATIONS

Address the ethical considerations of your research to satisfy the Committee that the research protocol gives adequate consideration to participants' welfare, rights, beliefs, perceptions, customs and that cultural heritage, both individual and collective, will be respected in the course of your research. Your response should address the following issues:

Feedback of results to participants and publication of the results, if this planned.

(for more detail, refer to NS 1 and the Application Guidelines)

Post trial follow-up.

How will voluntary participation be ensured?
Is active consent being sought from all participants for all aspects of the research involving them? If No, why not?
Are any participants in a dependent relationship with the researcher, the institution or the funding body (for example the researcher's clinical patients/clients or students; employees of the institution; recipients of services provided by the funding body)? Yes \(\square\$ No \(\square\$
If YES: What steps will be taken to ensure that participants are free to participate or refuse to participate in the research?
Is it anticipated that all participants will have the capacity to consent to their participation in the research?
If NO: Please explain why (e.g. children, incompetent participants, etc.) and explain how proxy or substitute consent will be obtained from the person with legal authority to consent on behalf of the participant.
How will participants' privacy be protected during the recruitment process, or access to tissue samples, or access to records?
Will any part of the research activities be placed on an audiotape, film, photograph, video-tape, cd, dvd, memory stick or other media? Yes No
If YES:To what purpose will the audiotape, film, photograph, video-tape, cd, dvd, memory stick or other media be used? For what audience(s) will the audiotape, film, photograph, video-tape, cd, dvd, memory stick or other media be exhibited?
What are the benefits and risks to participants and how will risks be minimised?
How does the project address the participants' freedom to discontinue participation? Will there be any adverse effects on participants if they withdraw their consent and will they be able to withdraw data concerning themselves if they withdraw their consent?
Are there any potential conflicts of interest for the researchers?
Will the research involve payments/rewards/inducements to participants?
How will confidentiality/anonymity of information received be ensured?
Any other ethical issues specific to your research?
STORAGE, ACCESS AND DISPOSAL OF DATA Describe what research data will be stored, where, for what period of time, the measures that will be pu in place to ensure security of the data, who will have access to the data, and the method and timing of disposal of the data.

18

Describe what research data will be stored, where, for what period of time, the measures that will be pu
in place to ensure security of the data, who will have access to the data, and the method and timing of
disposal of the data.

19 DECLARATION BY APPLICANTS

- In signing this application, I declare that the research protocol conforms to the *National Statement* on *Ethical Conduct in Research Involving Humans*, 2007, which I have read.
- 2. Where I am the project supervisor for the research described herein that will be conducted by a student of a university or other tertiary institution in Queensland, I declare that I have provided guidance to the student in the design, methodology and consideration of ethical issues of the proposed research.
- I make this application on the basis that the information it contains is confidential and will be used by Uniting Health*Care* for the purposes of ethical review and monitoring of the research project described herein, and to satisfy reporting requirements to regulatory bodies. The information will not be used for any other purpose without my prior consent.

All investigators named at Q3 and Q4 are to sign this declaration.

	Name	Signature	Date
Chief			
investigator/			
project supervisor			
Investigator 2			
\mathcal{E}			
Investigator 3			
Investigator 4			
-			
T			
Investigator 5			
Investigator 6			



Human Research Ethics Committee

Initial Application for Ethics Approval for Research Involving Humans

APPENDIX A

CLINICAL TRIALS

NOTE:

To be completed by applicants where the proposed research is a clinical trial of: drugs; natural, herbal, homeopathic or complementary therapies; therapeutic devices; innovative therapy/ intervention or a departure from standard treatment/care.

Applicants must demonstrate that the proposed research complies with Sections 12 and 13 of the *National Statement on Ethical Conduct in Research Involving Humans*, 2007, available at http://www.health.gov.au/nhmrc/issues/researchethics.htm and the *Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95)*, available at http://www.health.gov.au:80/tga/docs/html/ich13595.htm

Name: Title / first name / family name HORT TITLE OF PROJECT (as per Question 1 of the Initial Application 1) PIALS OF INNOVATIVE THERAPY/INTERVENTION, OR DEPARTUREMENT/CARE, GO TO Question 6.		TANDARD
VIALS OF INNOVATIVE THERAPY/INTERVENTION, OR DEPARTURE		TANDARD
	ES FROM S	IANDARD
ALIVIT CIME, GO TO Question o.		midnic
ist any drugs, natural/complementary therapies, or therapeutic dev		
etails of their Australian marketing approval status, including approdes of administration.	oved indica	tions, dosag
lodes of administration.		
the drugs, natural/complementary therapies, or therapeutic devices ustralia, will they be used in accordance with their approval?	s are approv	ved for use i
ustrana, win they be used in accordance with their approvar.	Yes [] No
NO: Explain how the proposed use is outside the conditions of approva	l and provid	e justificatio
oposed use.		
Vill the trial be registered with the Therapeutic Goods Administration	_	7
Vill the trial be registered with the Therapeutic Goods Administration inical Trial Notification (CTN) Scheme? YES, complete as far as possible, and attach the CTN application form – section the ethics committee approves your protocol.	Yes] No

TRIAL SPONSOR Is the trial sponsored, eg by a drug company or device manufacturer?	Yes		No	
If YES, who is the sponsor? Important: please provide name, address of spon	nsor and	<u>contact</u>	person.	
Will the Medicines Australia Compensation Guidelines for Injury apply? (see http://www.apma.com.au/headers/publications.html .	Yes		No	
Attach two originals of a document indemnifying Uniting Church in Australia Pro The document should comply with the Medicines Australia Form of Indemnity for (see http://www.apma.com.au/headers/publications.html).				
Provide details of the trial budget relating to payments to medical staf participants, and payments to researchers, institutions or organisation	ns involv	ed in th	ie resea	rc
	ns involved the su	ed in th pplier o	ie resea	rc
participants, and payments to researchers, institutions or organisation there is any business or similar association between the researcher and	ns involved the su	ed in th pplier o	ie resea	rc
participants, and payments to researchers, institutions or organisation there is any business or similar association between the researcher and surgical or other therapeutic device to be used in the trial, this should	ns involved the sure description	ed in th pplier o	ie resea	rc
participants, and payments to researchers, institutions or organisation there is any business or similar association between the researcher and surgical or other therapeutic device to be used in the trial, this should TRIAL SITES	ns involved the sure description	ed in th pplier o	ie resea	rc
participants, and payments to researchers, institutions or organisation there is any business or similar association between the researcher and surgical or other therapeutic device to be used in the trial, this should TRIAL SITES List all sites where the trial will be conducted, including international	ns involved the sure description	ed in th pplier o	ie resea	rc
participants, and payments to researchers, institutions or organisation there is any business or similar association between the researcher and surgical or other therapeutic device to be used in the trial, this should TRIAL SITES List all sites where the trial will be conducted, including international DOCUMENTS TO BE ATTACHED:	s involved the surple descriptions in the surple description sites.	red in the	ie resea	g o
participants, and payments to researchers, institutions or organisation there is any business or similar association between the researcher and surgical or other therapeutic device to be used in the trial, this should TRIAL SITES List all sites where the trial will be conducted, including international DOCUMENTS TO BE ATTACHED: Full Clinical Protocol – ten copies For non-registered drugs or devices, the Investigator Drug Brochure or organisation.	s involved the super description of the super	red in the pplier of ribed.	ie resea	g o